, Tracking Stock Market Picks
Enter Symbol:

down 37.31 %

OREXIGEN THERAPEUTIC (OREX) rated Underperform by BofA/Merrill

Posted on: Friday,  Dec 11, 2015  10:25 AM ET by BofA/Merrill

BofA/Merrill rated Underperform OREXIGEN THERAPEUTIC (NASDAQ: OREX) on 12/11/2015, when the stock price was $1.73. Since
then, OREXIGEN THERAPEUTIC has gained 59.54% as of 12/11/2015's recent price of $2.76.
If you would have followed this BofA/Merrill's recommendation on OREX, you would have lost 37.31% of your investment in 0 days.

Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. The combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. Contrave is a fixed dose combination of naltrexone SR and bupropion SR. Empatic is a fixed dose combination of zonisamide SR and bupropion SR.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/11/2015 10:25 AM Sell
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy